Progress toward a group B streptococcal vaccine

Joon Young Song, Jae Hyang Lim, Sangyong Lim, Zhi Yong, Ho Seong Seo

    Research output: Contribution to journalReview articlepeer-review

    26 Citations (Scopus)


    Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.

    Original languageEnglish
    Pages (from-to)2669-2681
    Number of pages13
    JournalHuman Vaccines and Immunotherapeutics
    Issue number11
    Publication statusPublished - 2018 Nov 2


    • Streptococcus agalactiae
    • group B Streptococcus
    • maternal immunization
    • vaccine

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Pharmacology


    Dive into the research topics of 'Progress toward a group B streptococcal vaccine'. Together they form a unique fingerprint.

    Cite this